Pharming Group NV
AEX:PHARM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (2.9), the stock would be worth €1.4 (3% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 3 | €1.44 |
0%
|
| 3-Year Average | 2.9 | €1.4 |
-3%
|
| 5-Year Average | 2.3 | €1.1 |
-23%
|
| Industry Average | 14.6 | €7.14 |
+395%
|
| Country Average | 1.8 | €0.89 |
-38%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
€969.8m
|
/ |
Jan 2026
$376.1m
|
= |
|
|
€969.8m
|
/ |
Dec 2026
$413.9m
|
= |
|
|
€969.8m
|
/ |
Dec 2027
$424.3m
|
= |
|
|
€969.8m
|
/ |
Dec 2028
$381.6m
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| NL |
|
Pharming Group NV
AEX:PHARM
|
1B EUR | 3 | 414.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 691 034.4 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.6B USD | 6.7 | 84.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.9B USD | 6.2 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
165.4B USD | 5.9 | 19.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 092.7 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.9B USD | 8.6 | 28.1 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79B USD | 4 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42B EUR | 10.8 | 38 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.1B AUD | 3.4 | 30.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 19.6 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.1 |
| Median | 1.8 |
| 70th Percentile | 4.2 |
| Max | 483 448.2 |
Other Multiples
Pharming Group NV
Glance View
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 321 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
